Business
Home prices are getting slightly more affordable, but down payments are still holding buyers back
Mortgage rates are lower, home prices are easing and there is more supply on the market for sale. All of that adds up to improved affordability for today’s homebuyers. Saving for a down payment, however, is still the biggest hurdle for first-time buyers.
Prices nationally are basically flat compared with where they were a year ago, according to Parcl Labs, which runs daily studies of U.S. home prices. They dipped into negative territory earlier this month and are now just 0.3% higher year over year.
The latest S&P Cotality Case-Shiller home price index, which reflects pricing from October, showed large disparities among metropolitan markets. Of the top 20 markets it highlights, Chicago; New York; and Cleveland had the biggest gains. Meanwhile eight cities showed prices in negative territory, with Tampa, Florida; Phoenix; and Dallas seeing the biggest losses.
“National home prices also continue to lag consumer inflation, as October’s CPI is estimated around 3.1% (based on a provisional index the U.S. Treasury announced due to the federal data shutdown) – roughly 1.8 percentage points higher than the latest housing appreciation. In real terms, that gap implies a slight decline in inflation-adjusted home values over the past year,” explained Nicholas Godec, head of fixed income tradables and commodities at S&P Dow Jones Indices, in a release.
Mortgage rates, too, are coming down.
The average on the 30-year fixed mortgage is currently at 6.19%, according to Mortgage News Daily. It started this year well over 7%. That decline means significant savings for homebuyers.
For example, for a buyer putting down 20% on a $410,000 home (right around the national median), the monthly payment today is $200 less on average than it would have been a year ago. Weaker prices and lower rates are changing the math on what first-time buyers can afford.
The typical homebuyer now needs seven years to save for a down payment, according to Realtor.com. That’s down from the recent peak of 12 years in 2022, but still roughly double pre-pandemic levels, partly because the personal savings rate is so much lower than it was in 2020.
Down payments continue to be the biggest hurdle to homeownership, which in the second half of this year fell to 65%, according to the U.S. Census, the lowest level since 2019.
But an improved supply of homes for sale is adding momentum to the market. Active listings are now about 12% higher than they were a year ago, according to Realtor.com, but still 6% lower than they were just pre-pandemic.
And buyers appear to be responding. Pending home sales, which count signed contracts on existing homes, rose more than expected in November. They were 3.3% higher than October, 2.6% higher than November 2024 and hit the highest level in nearly three years, according to the National Association of Realtors.
“Improving housing affordability–driven by lower mortgage rates and wage growth rising faster than home prices–is helping buyers test the market. More inventory choices compared to last year are also attracting more buyers to the market,” said Lawrence Yun, chief economist for the Realtors, in a release.
Business
FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals
Food and Drug Administration Commissioner Marty Makary warned that the U.S. is falling behind China in early-stage drug development and called for reforms that could streamline the process for starting trials on new treatments.
In an interview with CNBC on Wednesday, Makary specifically pointed to three bottlenecks that he said cause the U.S. to fall behind on those early drug trials.
These include hospital contracting as well as ethical reviews and approvals, both of which he called “clunky processes that take too long and are leaving us noncompetitive with the countries that are moving a lot faster.” He also pointed to the process for submitting and receiving approvals for Investigational New Drug, or IND, applications, which companies submit to test a product in humans.
“We walked into a mess,” Makary said, referring to how behind China the U.S. was in terms of Phase 1 clinical trials conducted in 2024.
Food and Drug Administration Commissioner Marty Makary speaks in the Oval Office at the White House on Jan. 29, 2026.
Samuel Corum | Getty Images
He said the FDA is “looking at everything,” such as whether it can partner with health systems and academic medical centers on the pre-IND process. That refers to when companies consult the FDA before formally filing an application.
Makary said the Trump administration should “partner with industry to help them deliver more cures and meaningful treatments for the American public because that is a common bipartisan goal that we all want. And we’re going to get it done in this administration.”
China’s biotech ecosystem has flourished over the last several years, driven by massive state investment, a vast talent pool and accelerated regulatory reforms. Once known for being a low-cost manufacturing base that pumps out copycats, China is rapidly evolving into a global innovation powerhouse.
Data from Global Data and Morgan Stanley shows that China now conducts more clinical trials than the U.S., accounts for nearly a third of new global drug approvals and is on pace to reach 35% of FDA approvals by 2040.
U.S. policymakers have been under pressure to take steps to boost innovation domestically.
Business
Mark Zuckerberg arrives to testify in social media addiction trial
In one such case, 29 state attorney generals are pushing a California federal court to demand that the platforms make a number of changes immediately, before any trial, including forcing Meta to remove all accounts known to belong to users under 13 years of age.
Business
India eyes diversification of crude oil sources; Piyush Goyal says would ‘love’ high-quality coking coal from US – The Times of India
India is looking to diversify its sources of crude oil, Commerce Minister Piyush Goyal has said. Goyal’s comments assume significance in light of the India-US trade deal joint statement which lowers tariffs on Indian exports to 18%. The Donald Trump administration has also removed the 25% penal tariffs on India on the condition that it stops buying crude oil from Russia.India’s crude imports from Russia have dropped since the US imposed sanctions on two major Russian oil firms in late 2025. According to reports, the share of Russian crude in India’s oil imports has dropped to the lowest level since late 2022 and analysts expect the numbers to drop further in the coming months.
India would ‘love’ high-quality coking coal from US
Piyush Goyal said India is looking to broaden its sourcing of crude oil and coking coal and would welcome supplies of premium-quality coking coal from the United States.Also Read | 18% tariffs, boost to exports, agriculture protected: How India benefits from trade deal with US? Explained“We want to diversify our oil sources. I want to diversify the source of coking coal for example. I am dependent on 2 or 3 geographies (for that) and prices keep fluctuating. I would love to have American coking coal which is high quality coming to India,” he said according to a PTI report.He noted that the US is well positioned to supply several products that are critical for India’s economic growth, including graphics processing units used in artificial intelligence, infrastructure and equipment for data centres, and high-performance computing systems.Goyal said India can produce goods in areas where US manufacturers may not be competitive, while America can serve as an important provider of technology and investment capital.Also Read | Trump removes 25% penal tariff: What happens if India stops buying Russian crude oil?He added that demand for aircraft from the US is already estimated at about $100 billion over the next five years, with additional capacity required to expand domestic aviation and help lower fares.Under the proposed interim trade pact with the United States, India has conveyed its intent to procure goods worth $500 billion from America over the next five years. An Indian delegation is scheduled to travel to the US next week to conclude the legal drafting of the agreement, which is expected to be signed in March.Piyush Goyal said entering into a trade agreement with the US would be beneficial for India, noting that it would create significant opportunities for domestic businesses, particularly in labour-intensive sectors and technology-driven services.Referring to India’s free trade agreements, Goyal noted that nine such pacts have been concluded over the past four years. He added that these deals were negotiated from a position of confidence, emphasising that India now engages in trade talks assertively, without defensiveness, and with a focus on long-term interests.
-
Business1 week agoAye Finance IPO Day 2: GMP Remains Zero; Apply Or Not? Check Price, GMP, Financials, Recommendations
-
Business1 week agoGold price today: How much 18K, 22K and 24K gold costs in Delhi, Mumbai & more – Check rates for your city – The Times of India
-
Fashion1 week agoComment: Tariffs, capacity and timing reshape sourcing decisions
-
Business6 days agoTop stocks to buy today: Stock recommendations for February 13, 2026 – check list – The Times of India
-
Fashion7 days agoIndia’s PDS Q3 revenue up 2% as margins remain under pressure
-
Fashion1 week agoSaint Laurent retains top spot as hottest brand in Q4 2025 Lyst Index
-
Politics6 days agoIndia clears proposal to buy French Rafale jets
-
Tech1 week agoRemoving barriers to tech careers
